Is neutrophil gelatinase associated lipocalin useful in hepatitis C virus infection?

Strazzulla, Alessio; Coppolino, Giuseppe; Fatta, Concetta Di; Giancotti, Francesca R.; D’Onofrio, Giuseppina; Postorino, Maria Concetta; Mazzitelli, Maria; Mammone, Selma Valerie; Gentile, I.; Rivoli, Laura; Palella, Eleonora; Gravina, Tiziana; Costa, Cristina; Pisani, Vincenzo; Maria, Vincenzo De; Barreca, Giorgio Settimo; Marascio, Nadia; Focà, Alfredo; Fuiano, Giorgio; Gulletta, Elio; Torti, Carlo

doi:10.4254/wjh.v8.i19.815

Cited by 7 publications

(11 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, we did not find a significant correlation between serum NGAL and the viral load, suggesting that renal affection in chronically HCV infected patients has no relation to the viral load. Similarly, Strazzulla et al did not find any correlation between serum NGAL and the burden of HCV RNA [21]. is is supported by previous studies which documented that, even with undetectable HCV RNA, occult hepatitis C may be the cause of a proportion of glomerulonephropathies [22,23].…”

Section: Discussionmentioning

confidence: 78%

“…Our results showed that serum NGAL was significantly higher in patients with eGFR < 60 ml/min per 1.73 m 2 compared to patients with eGFR 60-90 or >90 ml/min per 1.73 m 2 . Strazzulla et al reported similar results [21]. In contrast, Alhaddad et al observed a significantly lower plasma NGAL in HCV-positive cirrhotic patients with eGFR < 60 ml/min compared to cirrhotic patients with eGFR ≥ 60 ml/min [25].…”

Section: Discussionmentioning

confidence: 81%

“…ey found the same observation in their previous study which was conducted on patients with chronic hepatitis C treated with DAAs other than sofosbuvir-based regimen. ey explained that by either drug nephrotoxicity or inflammation due to the activity of antiviral drugs [21].…”

Section: Discussionmentioning

confidence: 99%

“…Despite these findings, they found that plasmatic NGAL was statistically correlated with eGFR in the overall population. ey mentioned that it is difficult to explain apparent discrepancies and concluded that further studies should evaluate the rate of concordance between the two methods in diverse stages of liver disease [21].…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir

Nada

Abbasy

Sabry

et al. 2020

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

Background. Direct-acting antivirals (DAAs) made a drastic change in the management of HCV infection. Sofosbuvir is one of the highly potent DAAs, eliminated mainly through the kidney. But concerns about renal safety during treatment may limit its use. Neutrophil gelatinase-associated lipocalin (NGAL) has been proven as a predictor of renal tubular injury. Hence, the aim of this work was to assess serum neutrophil gelatinase-associated lipocalin (NGAL) in HCV-positive patients before and after treatment with the sofosbuvir-based antiviral regimen. Methods. This prospective study included 87 Egyptian patients with chronic HCV infection treated with sofosbuvir plus daclatasvir with or without ribavirin for 12 weeks. Serum NGAL was measured before and at the end of treatment (EOT). Analysis of NGAL and estimated glomerular filtration rate (eGFR) evolution was done. Results. Our results showed a statistically significant decrease in serum NGAL (P=0.02) with a nonsignificant reduction in eGFR (P=0.06). Moreover, changes in serum NGAL levels (baseline compared to EOT) in patients ranked by KDIGO-CKD classification showed a significant decrease in stages 1 and 2 (P=0.14 and 0.034, respectively) and a nonsignificant decrease in stage 3 (P=0.25). Also, eGFR changes after treatment in patients ranked by the same classifications showed a nonsignificant reduction in all stages (P>0.05). Conclusions. Sofosbuvir appears to have no nephrotoxic effects and is safe to treat patients with chronic HCV infection.

show abstract

Section: Discussionmentioning

confidence: 78%

Section: Discussionmentioning

confidence: 81%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir

Nada

Abbasy

Sabry

et al. 2020

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

show abstract

“…Yet, the Cockroft-Gault equation is still largely used for drug adjustment recommendations, because kidney function was estimated by this formula in the majority of pharmacokinetics studies (38,39). New markers of tubular dysfunction, such as neutrophil gelatinase-associated lipocalin (NGAL), may be used to evaluate kidney damage during TDF therapy (40)(41)(42). In the past, various studies have been published demonstrating the usefulness of NGAL as an early biomarker of tubular damage in HIV-infected patients treated with TDF (43)(44)(45)(46).…”

Section: Dose Adjustment Of Tdf and Early Diagnosis Of Tdf-related Rementioning

confidence: 99%

Renal Concerns in the Treatment of Chronic Hepatitis B with Tenofovir

Coppolino

Cernaro

Rivoli

et al. 2017

jrenhep

Self Cite

View full text Add to dashboard Cite

Tenofovir, a third generation oral nucleos(t)ide analogue, currently represents one of the first-line drugs recommended for treating chronic hepatitis B virus (HBV) infection. After oral administration, tenofovir is mostly excreted in the urine by glomerular filtration and proximal tubular secretion. Hence, an impaired kidney function may lead to an increased renal exposure to the drug in patients with coexistent renal damage. This could further worsen kidney disease through different mechanisms of nephrotoxicity such as mitochondrial DNA depletion and tubular cytotoxicity. Despite several studies performed so far to assess tenofovir-related renal toxicity, data in HBV patients are not yet conclusive. Screening of risk factors for kidney disease before starting therapy and a careful monitoring of serum creatinine, glomerular filtration rate, serum phosphate and urine analysis during treatment are advocated to adjust the dose or stop treatment if needed. New biomarkers of tubular injury, such as neutrophil gelatinase associated lipocalin, could become helpful in the future for the timely identification and risk stratification of renal damage induced by tenofovir.

show abstract

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)

Manna

2018

J Nephrol

View full text Add to dashboard Cite

Is neutrophil gelatinase associated lipocalin useful in hepatitis C virus infection?

Abstract: Our results suggest that NGAL should be further evaluated as an adjunct marker of kidney function in these patients.

Cited by 7 publications

References 35 publications

Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir

Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir

Renal Concerns in the Treatment of Chronic Hepatitis B with Tenofovir

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)

Contact Info

Product

Resources

About